Arrow: Carfilzomib Dosing In Frail R/R Multiple Myeloma Patients

ARROW: carfilzomib dosing in frail R/R multiple myeloma patients

VJHemOnc – Video Journal of Hematology & HemOnc

Safety and efficacy of once-weekly carfilzomib dosing in frail patients: Phase 3 ARROW

International Myeloma Foundation

A.R.R.O.W. study: carfilzomib dosing in frail MM patients

VJHemOnc – Video Journal of Hematology & HemOnc

High-dose carfilzomib recaptures response in r/r multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Real-world use of carfilzomib for R/R myeloma patients

VJHemOnc – Video Journal of Hematology & HemOnc

ARROW: once vs. twice weekly carfilzomib for MM

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Chari Discusses Carfilzomib Dosing in Myeloma

Dr. Berenson on Weekly Carfilzomib For Patients With R/R Multiple Myeloma

Adding Carfilzomib to R/R Myeloma Regimens

Dr. Davies on Carfilzomib Dosage in Multiple Myeloma

Dr. Richter Discusses the Administration of Carfilzomib

MRD negativity rates following carfilzomib, dex & dara in R/R myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Carfilzomib and panobinostat for R/R multiple myeloma: Phase I results

VJHemOnc – Video Journal of Hematology & HemOnc

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

How important is the FDA approval of once-weekly dosage of Kyprolis for multiple myeloma patients?

International Myeloma Foundation

Promising results for isatuximab with carfilzomib in R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with RR multiple myeloma

International Myeloma Foundation

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

The American Society of Hematology

Dr. James Berenson Discusses the Carfilzomib (Kyprolis) Toxicity Profile

Dr. Mateos on Frail Patients With Multiple Myeloma in the ARROW Trial